TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2024-06-04
劉俊人Liu, Chun-Jen
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
jiun0924@gmail.com
發表文獻
74筆
61
Liu CH, Shih YL, Yang SS, Lin CL, Fang YJ, Cheng PN, Chen CY, Peng CY, Hsieh TY, Chiu YC, Su TH, Liu CJ, Yang HC, Chen PJ, Chen DS, Kao JH. Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. J Gastroenterol Hepatol. 2019 Nov;34(11):1977-1983. doi: 10.1111/jgh.14672. Epub 2019 May 27. PMID: 30931537.
62
Wang YH, Chuang YH, Wu CF, Jan MC, Wu WJ, Lin CL, Liu CJ, Yang YC, Chen PJ, Lin SM, Tsai MH, Huang YW, Yu MW. Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. Hepatology. 2019 Apr;69(4):1412-1425. doi: 10.1002/hep.30339. Epub 2019 Feb 19. PMID: 30382583.
63
Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. J Gastroenterol Hepatol. 2019 Dec;34(12):2179-2186. doi: 10.1111/jgh.14705. Epub 2019 Jun 18. PMID: 31062879.
64
Li YT, Wu HL, Kao JH, Cheng HR, Ho MC, Wang CC, Chen PJ, Chen DS, Liu CJ. Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Hepatology. 2019 Jul;70(1):184-197. doi: 10.1002/hep.30581. Epub 2019 Apr 14. PMID: 30802976.
65
Hu KC, Wu MS, Chu CH, Wang HY, Lin SC, Liu CC, Su TH, Liao WC, Chen CL, Liu CJ, Shih SC. Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. Clin Infect Dis. 2019 May 30;68(12):2105-2113. doi: 10.1093/cid/ciy591. Erratum in: Clin Infect Dis. 2019 Jun 18;69(1):195. PMID: 30566695.
66
Liu CH, Su TH, Liu CJ, Hong CM, Yang HC, Tseng TC, Chen PJ, Chen DS, Kao JH. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. J Gastroenterol Hepatol. 2019 Sep;34(9):1620-1625. doi: 10.1111/jgh.14615. Epub 2019 Feb 17. PMID: 30693965.
67
Su TH, Yang HC, Tseng TC, Chou SW, Lin CH, Liu CH, Liu CJ, Chen CL, Kao JH. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. Mov Disord. 2019 Dec;34(12):1882-1890. doi: 10.1002/mds.27848. Epub 2019 Sep 10. PMID: 31505068.
68
Tseng TC, Shih YF, Liu CJ. A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):495-496. doi: 10.1016/S2468-1253(19)30118-9. Epub 2019 Apr 9. PMID: 30975476.
69
Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc. 2019 Feb;118(2):556-564. doi: 10.1016/j.jfma.2018.11.007. Epub 2018 Dec 5. PMID: 30527566.
70
Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019 Jan;118(1 Pt 1):7-38. doi: 10.1016/j.jfma.2018.11.008. Epub 2018 Dec 6. PMID: 30527436.
